Screening for ovarian cancer

References

• Office for National Statistics. Cancer Statistics: Registrations (Series MB1.24). The Stationary Office, London, UK (1997).
   Google Scholar
• Mosby CV Advanced epithelial ovarian cancer. In: Clinical Gynaecologic Oncology (5th Frlition). DiSaia PJ, Creasman WT (Eds), Mosby, St. Louis, MI, USA, 300 (1997).
   Google Scholar
• Werness BA, Eltabbakh GH. Familial ovarian cancer and early ovarian cancer: biologic, pathologic and clinical features. Int.J Cynecol Pathol. 20(1), 48–63 (2001).
   PubMedGoogle Scholar
• Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl Cancer Inst. 94(18), 1365–1372 (2002).
   Google Scholar
• Rebbeck TR, Lynch HT, Neuhausen SL et al Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations N Engl. J. Med 346(21), 1616–1622 (2002).
   Google Scholar
• Skates SJ, Xu FJ, Yuh YH et al Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76\(Suppl. 10), 2004–2010 (1995).
   Google Scholar
• Xll Y, Shen Z, Wiper DW et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JA/V/A 280(8), 719–723 (1998).
   Google Scholar
• Mills GB, Eder A, Fang X et at Critical role of lysophospholipids in the pathophysiology, diagnosis and management of ovarian cancer. Cancer Treat. Res. 107,259–283 (2002).
   PubMedGoogle Scholar
• Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnosticbiomarker for ovarian cancer. JA/V/A 287(13), 1671–1679 (2002).
   Google Scholar
• Yousef GM, Diamandis ER Kallikreins, steroid hormones and ovarian cancer: is there a link? Minerva Endocrine' 27(3), 157–166 (2002).
   Google Scholar
• Robertson DM, Stephenson T, Pruysers E et al Inhibinsiactivins as diagnostic markers for ovarian cancer. 11/101. Cellular Endocrinol 191 (1), 97–103 (2002).
   Google Scholar
• Jain KK. Recent advances in oncoproteomics. CUIT: Opin. Mol filer. 4(3), 203–209 (2002).
   Google Scholar
• Ardekani AM, Liotta LA, Petricoin EF. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Md. Magri. 2 (4), 312–320 (2002) .
   Google Scholar
• Granberg S, Wikland M, Jonsson I. Macroscopic characterization of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Cynecol Oncol 35(2), 139–144. (1989).
   PubMedGoogle Scholar
• Menon U, Talaat A, Jeyarajah AR et al Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br. Cancer 80 (10), 1644–1647 (1999).
   Google Scholar
• Menon U, Talaat A, Rosenthal AN et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. Br. Obstet. Cynaecol. 107(2), 165–169 (1999).
   Google Scholar
• Bailey CL, Ueland FR, Land GL et al. The malignant potential of small cystic ovarian tumors in women over 50 years of age. Cynecol °rico' 69(1), 3–7 (1998).
   Google Scholar
• Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Cynecol Oncol. 82(1), 40–48 (2001).
   PubMed Web of Science ®Google Scholar
• Kuijak A, Kupesic S, Sparac V, Kosuta D. Three-dimensional ultrasonographic and power Doppler characterization of ovarian lesions. Ultrasound Obstet. Cynecol. 16(4), 365–371 (2000).
   Google Scholar
• Mol BVV, Boll D, De Kanter M et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Cynecol Oncol 80(2), 162–167 (2001).
   PubMedGoogle Scholar
• Kehoe S, Lowe D, Powell JE, Vincente B. Artificial neural networks and survival prediction in ovarian carcinoma. Eur. Cynaecol. Oncol 21(6), 583–584 (2000).
   Google Scholar
• Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. Sonographic prediction of malignancy in adnexal masses using an artificial neural network. Br. Obstet. Cynaecol. 106(1), 21–30 (1999).
   Google Scholar
• Clayton RD, Snowden S, Weston MJ et al. Neural networks in the diagnosis of malignant ovarian tumors. Br. J. Obstet. Cynaecol. 106(10), 1078–1082 (1999).
   Google Scholar
• Biagiotti R, Desii C, Vanzi E, Gacci G. Predicting ovarian malignancy: application of artificial neural networks to transvaginal and color Doppler flow US. Radiology 210(2), 399–403 (1999).
   PubMedGoogle Scholar
• Levy G, Levine P, Brennan J, Lerner JP, Monteagudo A, Timor-Tritsch IE. Color flow-directed Doppler studies of ovarian masses. Computer analysis. J. Repmd. Med. 43(10), 865–868 (1998).
   Google Scholar
• Newey VR. Classical versus artificial neural network analysis. Ultrasound Obstet. Cynecol. 10(1), 5–8 (1997).
   Google Scholar
• Bourne TH, Campbell S, Reynolds KM et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and color blood flow imaging. Br. Med. 306(6884), 1025–1029 (1993).
   PubMed Web of Science ®Google Scholar
• Pavlik EJ, Johnson TL, Depriest PD, Andrykowski MA, Kryscio RJ, Van Nagell JR. Continuing participation supports ultrasound screening for ovarian cancer. Ultrasound Obstet. Cynecol. 15(5), 354–364 (2000).
   Google Scholar
• DePriest PD, Gallion IIf I, Pavlik EJ, Kryscio RJ, Van Nagell JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Cynecol Oncol. 65(3), 408–414 (1997).
   Google Scholar
• Van Nagell JR, Gallion HH, Pavlik EJ, DePriest PD. Ovarian cancer screening.Cancer 76 (Suppl.), 2086-2091 (1995).
   Google Scholar
• Sato S, Yokoyama Y, Sakamoto T, Futagami M, Saito Y. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer89(3), 582–588 (2000).
   PubMedGoogle Scholar
• Hayashi H, Yaginuma Y, Kitamura S et al. Bilateral oophorectomy in asymptomatic women over 50 years old selected by ovarian cancer screening. Cynecol Obstet. Invest. 47(1), 58–64 (1999).
   Google Scholar
• Tabor A, Jensen FR, Bock JE, Hogdoll CK. Feasibility study of a randomized trial of ovarian cancer screening. J. Med. Screen. 1(4), 215–219 (1994).
   Google Scholar
• Campbell S, Bhan V, Royston P, Whitehead MI, Collins WP. Transabdominal ultrasound screening for early ovarian cancer. Br. Med. 299, 1363–1367 (1989).
   Google Scholar
• Millo R, Facca MC, Alberico S. Sonographic evaluation of ovarian volume in postmenopausal women: a screening test for ovarian cancer? Clin. Exp. Obstet. Cynecol. 16(2–3), 72–78 (1989).
   Google Scholar
• Goswamy RK, Campbell S, Whitehead MI. Screening for ovarian cancer. Clin. Obstet. Cynaecol. 10,621–643 (1983).
   Google Scholar
• Kurjak A, Shalan H, Kupesic S et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J. Ultrasound Med 13(4), 295–301 (1994).
   PubMedGoogle Scholar
• Vuento MH, Pirhonen JP, Makinen JI, Laippala PJ, Gronroos M, Salmi TA. Evaluation of ovarian fmdings in asymptomatic postmenopausal women with color Doppler ultrasound. Cancer 76(7), 1214–1218 (1995).
   PubMedGoogle Scholar
• Parkes CA, Smith D, Wald NJ, Bourne TH. Feasibility study of a randomized trial of ovarian cancer screening among the general population. J. Med. Screen. 1(4), 209–214 (1994).
   Google Scholar
• Holbert TR. Screening transvaginal ultrasonography of postmenopausal women in a private office setting. Am. Obstet. Cynecol 170(6), 1699–1703 (1994).
   Google Scholar
• Schingalia P, Brondelli L, Cicognani A, Buzzi G, Orsini LF, Bovicelli L. A feasibility study of ovarian cancer screening: does fine-needle aspiration improve ultrasound specificity? Tumori 80,181–187 (1994).
   PubMedGoogle Scholar
• Einhorn N, Sjovall K, Knapp RC et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet. Cynecol 80(1), 14–18 (1992).
   Google Scholar
• Jacobs IJ, Stabile I, Bridges J et al. Multimodal approach to screening for ovarian cancer. Lancetl (8580), 268–271 (1988).
   Google Scholar
• Jacobs IJ, Davies AP, Bridges J et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography Br Med. 306(6884), 1030–1034 (1993).
   Google Scholar
• Jacobs IJ, Skates SJ, Davies AP et al Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. Br. Med. J. 313, 1355–1358 (1996).
   Google Scholar
• Jacobs IJ, Skates SJ, Macdonald N et al. Screening for ovarian cancer: a pilot randomized controlled trial. Lancet 353, 1207–1210 (1999).
   PubMed Web of Science ®Google Scholar
• Grover S, Quinn MA, Weidman P, Koh H, Robinson HP, Rome R, Cauchi M. Screening for ovarian cancer using serum CA125 and vaginal examination: report on 2550 females. hit.j Gynecol Cancer5, 291–295 (1995).
   Google Scholar
• Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE. A combined approach for the early detection of ovarian cancer in asymptomatic women. Eur. j Obstet. Gynecol Reprod. Biol. 65(2), 221–225 (1996).
   Google Scholar
• Menon U, Jacobs IJ. Ovarian cancer screening in the general population. Ultrasound Obstet. Gyrkeol. 15(5), 350–353 (2000).
   Google Scholar
• Gohagan JK, Levin DL, Prorok PC, Sullivan D (Eds). The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization and status. Control Clin. Trials 21 (Suppl. 6), 251S-272S (2000).
   Google Scholar
• Karlan BY, Baldwin RL, Lopez-Luevanos E et at Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening. Am. I Obstet. Gynecol 180(4), 917–928 (1999).
   Google Scholar